Skip to main content
NIH funding notice PAR-23-279

Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)

Closed on November 17, 2024.

Posted
August 23, 2023
Close date
November 17, 2024
Activity codes
R01
Institutes taking part
NCI

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page names no earlier notice: it is new, or it does not say.

Replaced by PAR-25-069.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $693,075 in first-year total cost, median $693,075.

Most frequent study sections

  1. Cancer Prevention Study Section[CPSS]1

Most frequent institutions

  1. YALE UNIVERSITY1
Competing awards under PAR-23-279 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025Targeting pancreatic endocrine-exocrine signaling in cancer development with incretin mimetics1R01CA296916-01MUZUMDAR, MANDAR DEEPAKYALE UNIVERSITY, CT$693,075CPSS

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-23-279: Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) | ScienceDex | ConductScience